about
Fluorescent, Plasmonic, and Radiotherapeutic Properties of the 177Lu-Dendrimer-AuNP-Folate-Bombesin Nanoprobe Located Inside Cancer CellsMultifunctional targeted therapy system based on (99m) Tc/(177) Lu-labeled gold nanoparticles-Tat(49-57)-Lys(3) -bombesin internalized in nuclei of prostate cancer cells.Improved radiopharmaceutical based on 99mTc-Bombesin-folate for breast tumour imaging.Comparative Effect Between Laser and Radiofrequency Heating of RGD-Gold Nanospheres on MCF7 Cell Viability.Multifunctional radiolabeled nanoparticles for targeted therapy.99mTc-labeled PSMA inhibitor: Biokinetics and radiation dosimetry in healthy subjects and imaging of prostate cancer tumors in patients.Synthesis and evaluation of Lys¹(α,γ-Folate)Lys³(¹⁷⁷Lu-DOTA)-Bombesin(1-14) as a potential theranostic radiopharmaceutical for breast cancer.Two Novel Nanosized Radiolabeled Analogues of Somatostatin for Neuroendocrine Tumor Imaging.Ozone Dosage Effect on C6 Cell Growth: in Vitro and in Vivo Tests.Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.Design and biological evaluation of ⁹⁹mTc-N₂S₂-Tat(49-57)-c(RGDyK): a hybrid radiopharmaceutical for tumors expressing α(v)β(3) integrins.Multimeric system of 99mTc-labeled gold nanoparticles conjugated to c[RGDfK(C)] for molecular imaging of tumor α(v)β(3) expression.Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: implications for tumor angiogenesis.Design, preparation, in vitro and in vivo evaluation of (99m)Tc-N2S2-Tat(49-57)-bombesin: a target-specific hybrid radiopharmaceutical.Multimodal molecular 3D imaging for the tumoral volumetric distribution assessment of folate-based biosensors.99mTc-exendin(9-39)/octreotide: biokinetics and radiation dosimetry in healthy individuals.Clinical translation of a PSMA inhibitor for 99mTc-based SPECT.A freeze-dried kit formulation for the preparation of Lys(27)(99mTc-EDDA/HYNIC)-Exendin(9-39)/99mTc-EDDA/HYNIC-Tyr3-Octreotide to detect benign and malignant insulinomas.Preclinical Biokinetic Modelling of Tc-99m Radiophamaceuticals Obtained from Semi-Automatic Image Processing.Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: Biokinetics, Dosimetry, and Evaluation in Patients with Advanced Prostate Cancer(99m)Tc-labelled gold nanoparticles capped with HYNIC-peptide/mannose for sentinel lymph node detectionTheranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with (177)Lu and Conjugated to PeptidesMolecular targeting radiotherapy with cyclo-RGDFK(C) peptides conjugated to 177Lu-labeled gold nanoparticles in tumor-bearing mice177Lu-Bombesin-PLGA (paclitaxel): A targeted controlled-release nanomedicine for bimodal therapy of breast cancerSynthesis and Evaluation of 177Lu-DOTA-DN(PTX)-BN for Selective and Concomitant Radio and Drug-Therapeutic Effect on Breast Cancer Cells[99mTc-HYNIC-N-dodecylamide]: a new hydrophobic tracer for labelling reconstituted high-density lipoproteins (rHDL) for radioimagingSynergistic Antitumorigenic Activity of Calcitriol with Curcumin or Resveratrol is Mediated by Angiogenesis Inhibition in Triple Negative Breast Cancer XenograftsSynthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancerHead to head comparison performance of 99mTc-EDDA/HYNIC-iPSMA SPECT/CT and 68Ga-PSMA-11 PET/CT a prospective study in biochemical recurrence prostate cancer patientsHybrid (2D/3D) Dosimetry of Radiolabeled Gold Nanoparticles for Sentinel Lymph Node Detection in Patients with Breast Cancer
P50
Q33793282-71F2A5B0-6FCD-49DB-8C04-78B05AAB1F8FQ35241339-B2906B28-4ED4-4934-AE19-ADB2BBDE579FQ35866388-DBDF28F5-A8F0-4728-B207-7CA16E65CE54Q35872846-CE863E07-39A7-4347-BB53-E9124AB438A7Q38132886-1EF96C0B-544A-4647-BC31-9F1002329FEBQ38748087-958F7C53-4F4A-4E88-82A4-C322DF433DB5Q38821518-BDA89E90-9A89-4F3D-BD5A-A4A1D57E1B5BQ38835443-9CE7F032-8947-4E5E-AA5B-B198AE6346F0Q38944188-D5C45675-2024-4700-96CB-F9345BCAC0F3Q39043681-2F0B9DF9-AC8F-43B1-8A5F-7B3F109BEEE6Q39160437-9EE4091A-175D-4927-BE6B-FBFACA47C757Q39554653-E1ABBEB4-F7A2-4A8B-A895-582521C5C218Q44257443-48CC012B-AFE6-4865-AC03-689F8C16BCA2Q46037518-1672F407-A0D4-4AB8-8C52-D020A2D21574Q47592063-609F1D26-40CB-4CA1-9792-6902B167BBD8Q47913420-D517DAD6-B634-4985-8F4D-3E65D9222834Q52952002-ED927BB2-E265-4FB5-87F7-13D7963347A2Q53347251-D09594AE-51DE-4BD5-B98F-9E3C6FC9DCD0Q55040263-E402C736-3D87-4017-B064-48D7257D9A4CQ59811230-A10B76B7-2C54-468A-9C26-EE234B4EDC5AQ83160596-BB49E1D7-3A95-468A-BE95-43F446885B11Q86929965-339A95BC-6B4E-4DB0-B3DA-4E75342D133DQ87677383-70CBA43B-D24F-4296-B698-9DF40CEB6065Q90222863-19632A10-7248-46F2-BB15-B90ED180388BQ90383455-249DC55B-660A-49B0-9E4D-5F0C5261E93EQ90446608-008831CA-14CE-4920-A87F-423E5A854A5AQ91168530-FE6801C2-E88F-4480-96C5-5B8E9D6C5DCBQ91578448-4F5DA9DA-74F3-4FE9-A604-7ABCB251D126Q95360906-8049EDAC-6180-4255-A9DF-DD1D4043DB6EQ96134597-61C9253B-7EDF-4373-A9E5-C123FEF3029E
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Clara L Santos-Cuevas
@ast
Clara L Santos-Cuevas
@en
Clara L Santos-Cuevas
@es
Clara L Santos-Cuevas
@nl
type
label
Clara L Santos-Cuevas
@ast
Clara L Santos-Cuevas
@en
Clara L Santos-Cuevas
@es
Clara L Santos-Cuevas
@nl
prefLabel
Clara L Santos-Cuevas
@ast
Clara L Santos-Cuevas
@en
Clara L Santos-Cuevas
@es
Clara L Santos-Cuevas
@nl
P106
P1153
56013725800
P31
P496
0000-0001-5903-1598